FDA
-
-
-
-
-
-
-
Gritstone bio (GRTS) Issues Update to Comparative Phase 2b COVID-19 Trial
-
-
-
-
-
-
-
Gritstone Announces Updated Overall Survival Results from GRANITE Phase 1/2 Study and Poster at SITC 2022
-
-
-
-
-
-
-
Gritstone Reports Third Quarter 2021 Financial Results and Business Update
-
-
-
-
-
-
-
Gritstone Announces Management Changes, Including the Appointment of Celia Economides as Chief Financial Officer
-
-
-
-
-
-
-
Gritstone Oncology Reports Promising Early Immunogenicity Activity and Safety Data from its Phase 1 Studies Evaluating its Neoantigen-based Immunotherapies, GRANITE and SLATE
-
-
-
-
-
-
-
Gritstone Oncology Inc. (GRTS) Reports Clinical Acceleration of 'Off-The-Shelf' Personalized Neoantigen Immunotherapy Program (SLATE) Following FDA Feedback
-
-
-
-
-
-
-
Gritstone Oncology Announces First Patient Dosed in a Clinical Study Evaluating its Personalized Immunotherapy, GRANITE-001
-
322,897 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

